Abstract
Statistics show that among malignant tumors, pancreatic cancer has the poorest prognosis. Cancer has a low likelihood of survival, and early cancer diagnosis is challenging. The major therapies currently used include surgery, chemotherapy, and radiation, although the outcomes are not optimal. Treatments for pancreatic cancer using immunotherapy now appear more promising because to developments in molecular biology. The primary pancreatic cancer treatments will be analyzed and evaluated in this study, and it will be concluded that immunotherapy is the most promising course of action. The usage of patient range, toxicity, and other side effects are some of the difficulties, although it is still in the research and development stage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
